Tocilizumab for treatment-resistant depression in Brazil
Treatments studied
Part of Mental health clinical trials.
This trial tests if adding tocilizumab, a drug that blocks inflammation, can help people with depression that hasn't improved after two or more treatments. It is for adults in the Brazilian public health system who have signs of inflammation in their blood.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have depression that did not get better after at least two different treatments.
- You are willing to have blood drawn and avoid hard exercise for 3 days before visits.
- You have a depression severity score of 19 or higher and a blood inflammation marker (CRP) of 3 mg/L or more.
- You do not have bipolar disorder, personality disorder, active infections, autoimmune disease, or recent substance use.
- You are not pregnant or breastfeeding, and have no serious heart, liver, blood, or cancer history.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a medication called tocilizumab, which targets inflammation, to see if it can improve symptoms of major depression in people with signs of inflammation. You may be eligible if you have depression with a high monocyte count and significant loss of interest or pleasure.
This trial tests if cannabidiol (CBD) oil can help people with major depression that has not improved with standard antidepressants. You will take CBD oil or a placebo while continuing your current antidepressant treatment to see if it improves your symptoms.
This trial tests a JAK inhibitor (a type of anti-inflammatory drug) for depression that is linked to inflammation. If you have depression or bipolar depression and a high CRP level (a marker of inflammation), you may be eligible.
This study tests whether doctors can choose the best add-on immune-related treatment for people with major depressive disorder by using inflammation blood tests. It’s meant for people whose depression has not improved enough with their current antidepressant.
This trial tests if a medicine called infliximab, given through an IV, can help improve thinking and memory problems in people with moderate to severe depression who also have high inflammation levels. It aims to see if lowering inflammation can ease both mood and cognitive symptoms.
This Phase 2 study looks at whether lowering inflammation can help improve depression symptoms in adults living with HIV. You may be able to join if your HIV is well controlled and you are currently experiencing major depression (or a certain type of bipolar depression).
Hear when a new Treatment-Resistant Major Depressive Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.